Drug
Durvalumab clinical trials
Also written MEDI4736, Imfinzi and ZKAB001.
- studies test it
- 557
- open now
- 117
- in phase 3
- 68
- first study started
- 2010
Keep track of what changes. Save the durvalumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Durvalumab
- 449
Brand
- Imfinzi
- 143
Studies by the year they started
556 studies that test it; most in 2018 (66); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 17 |
| 2015 | 27 |
| 2016 | 43 |
| 2017 | 62 |
| 2018 | 66 |
| 2019 | 59 |
| 2020 | 61 |
| 2021 | 59 |
| 2022 | 34 |
| 2023 | 40 |
| 2024 | 40 |
| 2025 | 22 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 10
- Phase 1
- 160
- Phase 2
- 372
- Phase 3
- 68
- Phase 4
- 5
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 139 · Other 418
AstraZeneca (84) · MedImmune LLC (21) · M.D. Anderson Cancer Center (19) · National Cancer Institute (NCI) (15) · Memorial Sloan Kettering Cancer Center (12) · Canadian Cancer Trials Group (10) · Seoul National University Hospital (9) · University Health Network, Toronto (7)
Often tested with
Tested in the same studies.
Tremelimumab (126) · Olaparib (40) · Cisplatin (30) · Gemcitabine (23) · Paclitaxel (21) · Pembrolizumab (19) · Carboplatin (17) · Bevacizumab (14)
Studies
Open first, then newest update. How each study uses durvalumab is read from its arms, and is right about nine times in ten.
Testing it · 557
- Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06440993Written as Durvalumab
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Durvalumab
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Durvalumab
- Histotripsy in Biliary Tract CancerRecruitingNot applicableNYU Langone HealthNCT07853690Written as Durvalumab
- Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2National Cancer Center, JapanNCT07872722Written as Durvalumab
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06498635Written as Durvalumab
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.Not yet recruitingPhase 3AstraZenecaNCT07877818Written as Durvalumab
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034Written as Durvalumab
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingPhase 4AstraZenecaNCT07876817Written as Durvalumab
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerRecruitingPhase 2Alliance Foundation Trials, LLC.NCT07149363Written as Durvalumab 50 MG/ML
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Durvalumab
- Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaRecruitingPhase 2University of Wisconsin, MadisonNCT07766187Written as Durvalumab
- TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingPhase 2Filipa Lynce, MDNCT05795101Written as Durvalumab
- Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesRecruitingPhase 3Leiden University Medical CenterNCT05255653Written as Durvalumab
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingPhase 3Eli Lilly and CompanyNCT06890598Written as Durvalumab
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225Written as Durvalumab
- A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruitingPhase 2Mehmet AkceNCT06728410Written as Durvalumab
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingPhase 2John SfakianosNCT06503614Written as Durvalumab
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingPhase 1/2Mayo ClinicNCT03942328Written as Durvalumab
- Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingPhase 2Yuanquan YangNCT06263153Written as Durvalumab
See all 557 studies that test durvalumab →
Given in every arm · 147 — durvalumab is usual care beside what is tested
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Durvalumab
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07554339Written as Durvalumab
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Durvalumab
- Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)RecruitingPhase 2AstraZenecaNCT06960577Written as Durvalumab
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780137Written as Durvalumab
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingPhase 3Stanford UniversityNCT04585490Written as Durvalumab
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Johnson & Johnson Enterprise Innovation Inc.NCT06667908Written as Durvalumab
- RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II TrialRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT04105270Written as Durvalumab 1500 mg IV
- Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06287775Written as Durvalumab
- HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06858735Written as Durvalumab
- A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingPhase 2Canadian Cancer Trials GroupNCT03847649Written as Durvalumab
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06282575Written as Durvalumab
- Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyRecruitingPhase 2M.D. Anderson Cancer CenterNCT04892953Written as Durvalumab
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingPhase 1AmgenNCT07531095Written as Durvalumab
- AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic CancerRecruitingPhase 1Jonsson Comprehensive Cancer CenterNCT07619313Written as Durvalumab
- Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerRecruitingPhase 3NRG OncologyNCT05624996Written as Durvalumab
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406Written as Durvalumab
- Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung CancerNot yet recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07759492Written as Durvalumab
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT03011814Written as Durvalumab
- REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05632809Written as Durvalumab
Showing 20 of 147.
As the comparator · 21 — what is tested is compared with durvalumab
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Durvalumab
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357Written as Durvalumab
- A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingPhase 3Bristol-Myers SquibbNCT07361497Written as Durvalumab
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingPhase 3AstraZenecaNCT07221253Written as Durvalumab
- Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07765433Written as Durvalumab
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06880523Written as Durvalumab
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284Written as Durvalumab
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingPhase 3Taiho Pharmaceutical Co., Ltd.NCT07710885Written as Durvalumab
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223Written as Durvalumab
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT07036380Written as Gemcitabine + Cisplatin + Durvalumab
- A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07229625Written as Durvalumab Injection
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as Durvalumab
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Active, not recruitingPhase 2SCRI Development Innovations, LLCNCT06773910Written as Durvalumab
- A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT06333678Written as Durvalumab
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Hoffmann-La RocheNCT05170204Written as Durvalumab
- A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT04513925Written as Durvalumab
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04380636Written as Durvalumab
- AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerActive, not recruitingPhase 3AkesoNCT06591520Written as Durvalumab, Gemcitabine, Cisplatin
- Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerWithdrawnPhase 2ETOP IBCSG Partners FoundationNCT05718297Written as Durvalumab
- M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT03840902Written as Durvalumab
Showing 20 of 21.
Codes
What other systems call durvalumab · ClinicalTrials.gg INT000587
- MeSH (NLM) C000613593durvalumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 28X28X9OKVDURVALUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1919503Confirmed FDA, Wikidata
- Wikidata Q19904005durvalumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103194DurvalumabOne source FDA
- DrugBank DB11714One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613593 | durvalumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 28X28X9OKV | DURVALUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1919503 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19904005 | durvalumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103194 | Durvalumab | One source FDA |
| DrugBank | DB11714 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.